• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019-United States, Janua

tetano

Editor, Senior Moderator
PLoS One


. 2021 Apr 15;16(4):e0249901.
doi: 10.1371/journal.pone.0249901. eCollection 2021.
Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019-United States, January 17-February 29, 2020


Olivia L McGovern[SUP] 1 2 [/SUP], Mark Stenger[SUP] 1 [/SUP], Sara E Oliver[SUP] 1 [/SUP], Tara C Anderson[SUP] 1 [/SUP], Cheryl Isenhour[SUP] 1 [/SUP], Matthew R Mauldin[SUP] 1 [/SUP], Nia Williams[SUP] 1 [/SUP], Eric Griggs[SUP] 1 [/SUP], Tonny Bogere[SUP] 1 [/SUP], Chris Edens[SUP] 1 [/SUP], Aaron T Curns[SUP] 1 [/SUP], Joana Y Lively[SUP] 1 3 [/SUP], Yingtao Zhou[SUP] 1 4 [/SUP], Songli Xu[SUP] 1 [/SUP], Maureen H Diaz[SUP] 1 [/SUP], Jessica L Waller[SUP] 1 [/SUP], Kevin R Clarke[SUP] 1 [/SUP], Mary E Evans[SUP] 1 [/SUP], Elisabeth M Hesse[SUP] 1 [/SUP], Sapna Bamrah Morris[SUP] 1 [/SUP], Robert P McClung[SUP] 1 [/SUP], Laura A Cooley[SUP] 1 [/SUP], Naeemah Logan[SUP] 1 [/SUP], Andrew T Boyd[SUP] 1 [/SUP], Allan W Taylor[SUP] 1 [/SUP], Kristina L Bajema[SUP] 1 2 [/SUP], Stephen Lindstrom[SUP] 1 [/SUP], Christopher A Elkins[SUP] 1 [/SUP], Christopher Jones[SUP] 1 [/SUP], Aron J Hall[SUP] 1 [/SUP], Samuel Graitcer[SUP] 1 [/SUP], Alexandra M Oster[SUP] 1 [/SUP], Alicia M Fry[SUP] 1 [/SUP], Marc Fischer[SUP] 1 [/SUP], Laura Conklin[SUP] 1 [/SUP], Runa H Gokhale[SUP] 1 [/SUP]



Affiliations

Abstract

Background: The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020.
Methods: In this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17-February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios.
Results: A total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures.
Conclusions: These findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.
 
Back
Top Bottom